10 news items
Where Maravai LifeSciences Stands With Analysts
MRVI
9 May 24
0
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average
Baird Maintains Outperform on Maravai LifeSciences, Raises Price Target to $10
MRVI
9 May 24
Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and raises the price target from $8 to $10.
Craig-Hallum Initiates Coverage On Maravai LifeSciences with Buy Rating, Announces Price Target of $15
MRVI
10 Apr 24
Craig-Hallum analyst Christian Schwab initiates coverage on Maravai LifeSciences (NASDAQ:MRVI) with a Buy rating and announces Price Target of $15.
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
ABSI
AMD
BB
9 Apr 24
extension of strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6.
Taysha Gene Therapies, Inc
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
ARDX
DYAI
MEDS
28 Feb 24
-molecule kinase inhibitor targeting oncogenic RET fusions and wild-type RET fusions. GAVRETO has already received approval from the United States Food
c1n9xb
AAOI
ACCO
AKRO
23 Feb 24
a Neutral rating on the stock and raised its price target from $12 to $13.5.
ATN International, Inc
xr3rf5l2nc276zjbdverxb
AER
AXTI
MNPR
23 Feb 24
, gaining 37% to $1.5306 after the company announced preclinical data for its MNPR-101 radiopharma program targeting advanced cancers
331aipje51wmxkfqr ohl1sf1kr73
MRVI
23 Feb 24
RBC Capital analyst Conor McNamara maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and raises the price target from $12 to $14.
vbkich2
AER
AXTI
CRGEQ
23 Feb 24
were also up, gaining 52% to $1.70 after the company announced preclinical data for its MNPR-101 radiopharma program targeting advanced cancers
otu5axbq8y88hs9phcgx47f9ugkblvs
BKNG
BLMN
CVNA
23 Feb 24
emphasized the need for greater confidence in inflation converging towards the 2% target before considering rate cuts.
The lack of significant
- Prev
- 1
- Next